PharmaShots | Incisive News in 3 Shots

Subscribe Now

Qilu Pharmaceutical

Qilu Pharmaceutical Reports Results from the P-II Trial of QL1706 for Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Reports Results from the P-II Trial of QL1706 for Non-Small Cell Lung Cancer (NSCLC)

February 2, 2024

Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

December 2, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us